A year ago unthinkable, the market for mRNA-based Covid-19 vaccines appears to be headed for saturation, even though, or perhaps because, there now seem to be more...

Activist hedge fund Bluebell Capital Partners has joined activist investor Elliott Management, GlaxoSmithKline’s long-time nemesis, in trying to force a leadership...

CV2Cov, the next-generation Covid-19 vaccine under development by German biotech CureVac and UK drugs giant GSK, outperformed CureVac’s first-generation Covid shot in...

GlaxoSmithKline (GSK), the UK’s largest drugmaker, plans to establish a new life sciences campus within its R&D site at Stevenage, England. The company said it is...

The human medicines committee of the European Medicines Agency, CHMP, has begun a rolling review of the Covid-19 vaccine developed by Sanofi Pasteur, which following...

Emma Walmsley, CEO of GlaxoSmithKline, under attack from activist investor Elliott Management, has received the backing of the company’s board, which said it “strongly...

After seeing encouraging results with their adjuvanted recombinant Covid-19 vaccine candidate across all adult age groups in a recently completed Phase 2 trial, Sanofi...

Activist hedge fund Elliott Management, also known as Elliott Associates or Elliott Advisers, has a new target – GlaxoSmithKline (GSK). Over the past decade, the fund has...